CellCyte Genetics Retains InCap Group to Advise on Business Strategy and...(their professionals. The professionals a...)

Date:7/9/2008

their professionals. The professionals at InCap were deeply involved in many of Legg Mason, Inc.'s investment management acquisitions, which resulted in the firm being transformed from a modest regional securities brokerage firm to one of the ten largest asset management firms in the world. InCap's professionals have worked at other leading industry firms including Fidelity Investments, SEI Investments, PaineWebber, and Oppenheimer & Co. For more information, please visit http://www.incapgroup.com.

About CellCyte Genetics

CellCyte Genetics is a biotechnology company engaged in the discovery, development and commercialization of stem cell enabling therapeutic products. CellCyte is developing products to allow more efficient delivery and increased retention of adult stem cells to diseased organs, such as the heart. The goal of these therapies is to increase the number of stem cells delivered to a damaged organ, thereby markedly increasing organ healing and functional restoration. The Company's lead product, CCG-TH30, is being developed to send autologous bone marrow-derived (adult) stem cells to the heart of patients after a heart attack.

For further information see: http://www.cellcyte.com.

Symbol: OTCBB - CCYG; Frankfurt/Berlin Symbol - LK6 WKN. No.: A0MLCV.

Safe Harbor Statement

THIS NEWS RELEASE CONTAINS "FORWARD-LOOKING STATEMENTS", AS THAT TERM IS DEFINED IN SECTION 27A OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, AND SECTION 21E OF THE UNITED STATES SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. STATEMENTS IN THIS NEWS RELEASE, WHICH ARE NOT PURELY HISTORICAL, ARE FORWARD-LOOKING STATEMENTS AND INCLUDE ANY STATEMENTS REGARDING BELIEFS, PLANS, EXPECTATIONS OR INTENTIONS REGARDING THE FUTURE. EXCEPT FOR THE HISTORICAL INFORMATION PRESENTED HEREIN, MATTERS DISCUSSED IN THIS NEWS RELEASE CONTAIN FORWARD-
'/>"/>

SOURCE CellCyte Genetics Corporation Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related biology technology :

1. CellCyte Genetics to Present at 2008 San Francisco RedChip Small-Cap Investor Conference
2. CellCyte Genetics Corporation Announces Launch of Comprehensive Web site Powered by PRNewswire Investor Room Backend Technology
3. CellCyte Genetics Corp. Appoints Jay H. Traverse to Scientific Advisory Board as Clinical Consultant
4. CellCyte Genetics Corp. Continues to Move Its Technology Forward in Light of Plaintiff Law Firm Press Releases
5. Finkelstein Thompson LLP Announces Filing of Securities Fraud Class Action Against CellCyte Genetics Corporation
6. Hagens Berman Sobol Shapiro: Lawsuit Filed Against CellCyte Genetics Corporation
7. CellCyte Genetics Corp. Responds to Plaintiff Law Firm Press Releases
8. Hagens Berman Sobol Shapiro Announces Proposed Class-Action Lawsuit Against CellCyte
9. Hagens Berman Sobol Shapiro Investigating CellCyte
10. Patent on Technology for the Delivery of Stem Cells to the Human Heart Issued to CellCyte Genetics Corp. of Washington
11. CellCyte Genetics Corp. Forms Device Division to Develop and Manufacture Stem Cell Cultivation and Replication Products